CN112341397A - 新型吡嗪类衍生物或盐、异构体、其制备方法及用途 - Google Patents
新型吡嗪类衍生物或盐、异构体、其制备方法及用途 Download PDFInfo
- Publication number
- CN112341397A CN112341397A CN202010772942.7A CN202010772942A CN112341397A CN 112341397 A CN112341397 A CN 112341397A CN 202010772942 A CN202010772942 A CN 202010772942A CN 112341397 A CN112341397 A CN 112341397A
- Authority
- CN
- China
- Prior art keywords
- substituted
- unsubstituted
- compound
- ethyl
- pyrazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 150000003839 salts Chemical class 0.000 title claims abstract description 16
- 150000003216 pyrazines Chemical class 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 79
- -1 nitrogen oxide compound Chemical class 0.000 claims description 82
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 12
- 150000002431 hydrogen Chemical class 0.000 claims description 12
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 11
- 229910052805 deuterium Inorganic materials 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 8
- 229940002612 prodrug Drugs 0.000 claims description 8
- 239000000651 prodrug Substances 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims description 6
- 235000010290 biphenyl Nutrition 0.000 claims description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 125000001624 naphthyl group Chemical group 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 125000001544 thienyl group Chemical group 0.000 claims description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Cs2CO3 Substances [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 4
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
- 239000004327 boric acid Substances 0.000 claims description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 4
- 125000005518 carboxamido group Chemical group 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000005493 quinolyl group Chemical group 0.000 claims description 4
- 150000003254 radicals Chemical class 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 4
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 108010085082 sigma receptors Proteins 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 2
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims description 2
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims description 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 2
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- WLYPBMBWKYALCG-UHFFFAOYSA-N [2,4-bis(trifluoromethyl)phenyl]boronic acid Chemical group OB(O)C1=CC=C(C(F)(F)F)C=C1C(F)(F)F WLYPBMBWKYALCG-UHFFFAOYSA-N 0.000 claims description 2
- 125000005002 aryl methyl group Chemical group 0.000 claims description 2
- 125000003725 azepanyl group Chemical group 0.000 claims description 2
- 239000004305 biphenyl Substances 0.000 claims description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000003054 catalyst Substances 0.000 claims description 2
- 238000006555 catalytic reaction Methods 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000004988 dibenzothienyl group Chemical group C1(=CC=CC=2SC3=C(C21)C=CC=C3)* 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 239000002207 metabolite Substances 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 239000000543 intermediate Substances 0.000 claims 1
- 238000012360 testing method Methods 0.000 abstract description 64
- 241000699670 Mus sp. Species 0.000 abstract description 14
- 230000000202 analgesic effect Effects 0.000 abstract description 13
- 238000000338 in vitro Methods 0.000 abstract description 13
- 102000005962 receptors Human genes 0.000 abstract description 7
- 108020003175 receptors Proteins 0.000 abstract description 7
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 abstract description 6
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 abstract description 6
- 102100028656 Sigma non-opioid intracellular receptor 1 Human genes 0.000 abstract description 6
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 abstract description 5
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 abstract description 5
- 101710104750 Sigma non-opioid intracellular receptor 1 Proteins 0.000 abstract description 5
- 229940005483 opioid analgesics Drugs 0.000 abstract description 5
- 238000002474 experimental method Methods 0.000 abstract description 3
- 239000000014 opioid analgesic Substances 0.000 abstract description 3
- 102000017911 HTR1A Human genes 0.000 abstract description 2
- 101150015707 HTR1A gene Proteins 0.000 abstract description 2
- 238000004458 analytical method Methods 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract description 2
- 239000002287 radioligand Substances 0.000 abstract description 2
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 40
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 25
- 229960005181 morphine Drugs 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 19
- 208000002193 Pain Diseases 0.000 description 16
- 230000036407 pain Effects 0.000 description 16
- 238000005160 1H NMR spectroscopy Methods 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 12
- KPTRDYONBVUWPD-UHFFFAOYSA-N naphthalen-2-ylboronic acid Chemical compound C1=CC=CC2=CC(B(O)O)=CC=C21 KPTRDYONBVUWPD-UHFFFAOYSA-N 0.000 description 12
- 239000012131 assay buffer Substances 0.000 description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000000872 buffer Substances 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- 238000010998 test method Methods 0.000 description 7
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 208000000114 Pain Threshold Diseases 0.000 description 5
- 230000036592 analgesia Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000037040 pain threshold Effects 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- 239000012981 Hank's balanced salt solution Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 238000003825 pressing Methods 0.000 description 4
- 238000003653 radioligand binding assay Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 3
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 3
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 208000028017 Psychotic disease Diseases 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 238000013262 cAMP assay Methods 0.000 description 3
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000012499 inoculation medium Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 208000011117 substance-related disease Diseases 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100033868 Cannabinoid receptor 1 Human genes 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- 108090000137 Opioid Receptors Proteins 0.000 description 2
- 102000003840 Opioid Receptors Human genes 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- DMNOVGJWPASQDL-OAQYLSRUSA-N n-[(3-methoxythiophen-2-yl)methyl]-2-[(9r)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethanamine Chemical compound C1=CSC(CNCC[C@@]2(CC3(CCCC3)OCC2)C=2N=CC=CC=2)=C1OC DMNOVGJWPASQDL-OAQYLSRUSA-N 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 230000001235 sensitizing effect Effects 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- JKIGHOARKAIPJI-UHFFFAOYSA-N (3,4-dichlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C(Cl)=C1 JKIGHOARKAIPJI-UHFFFAOYSA-N 0.000 description 1
- QWQBQRYFWNIDOC-UHFFFAOYSA-N (3,5-difluorophenyl)boronic acid Chemical compound OB(O)C1=CC(F)=CC(F)=C1 QWQBQRYFWNIDOC-UHFFFAOYSA-N 0.000 description 1
- IQMLIVUHMSIOQP-UHFFFAOYSA-N (4-fluoro-2-methylphenyl)boronic acid Chemical compound CC1=CC(F)=CC=C1B(O)O IQMLIVUHMSIOQP-UHFFFAOYSA-N 0.000 description 1
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 102100036214 Cannabinoid receptor 2 Human genes 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000012488 Opiate Overdose Diseases 0.000 description 1
- 208000026251 Opioid-Related disease Diseases 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 229940124264 Sigma 1 receptor antagonist Drugs 0.000 description 1
- 229940127318 Sigma-1 Receptor Antagonists Drugs 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- UWDFWVLAHRQSKK-UHFFFAOYSA-N [3-(trifluoromethoxy)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC(OC(F)(F)F)=C1 UWDFWVLAHRQSKK-UHFFFAOYSA-N 0.000 description 1
- HUOFUOCSQCYFPW-UHFFFAOYSA-N [4-(trifluoromethoxy)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(OC(F)(F)F)C=C1 HUOFUOCSQCYFPW-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- YNCYPMUJDDXIRH-UHFFFAOYSA-N benzo[b]thiophene-2-boronic acid Chemical compound C1=CC=C2SC(B(O)O)=CC2=C1 YNCYPMUJDDXIRH-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 238000012669 compression test Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000004672 jump response Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003402 opiate agonist Substances 0.000 description 1
- 201000000988 opioid abuse Diseases 0.000 description 1
- 229940124636 opioid drug Drugs 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- ABMYEXAYWZJVOV-UHFFFAOYSA-N pyridin-3-ylboronic acid Chemical compound OB(O)C1=CC=CN=C1 ABMYEXAYWZJVOV-UHFFFAOYSA-N 0.000 description 1
- KATIRQRAVXTBNY-UHFFFAOYSA-N quinolin-4-ylboronic acid Chemical compound C1=CC=C2C(B(O)O)=CC=NC2=C1 KATIRQRAVXTBNY-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 108010080097 sigma-1 receptor Proteins 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical group C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- ARYHTUPFQTUBBG-UHFFFAOYSA-N thiophen-2-ylboronic acid Chemical compound OB(O)C1=CC=CS1 ARYHTUPFQTUBBG-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/18—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
新型吡嗪类衍生物或盐、异构体、其制备方法及用途。一种化合物,其为如式Ⅰ所示的化合物,其具有Sigma1受体拮抗作用,在体外受体亲和力方面,对sigma1R的体外亲和力均强。同时在对D2L放射性配体结合分析及5HT‑1A受体、CB1受体、CB2受体cAMP试验中,对这些受体亲和力均不佳,表现出较高的受体选择性。此外,在小鼠体内实验中,本发明提供的化合物还可增强阿片类镇痛剂的镇痛活性。
Description
技术领域
本发明涉及药物化学领域,具体涉及新型吡嗪类衍生物或其盐、异构体、其制备方法及其药物组合物在制备治疗和预防中的用途,尤其在疼痛、药物成瘾、阿片药物增效、精神病等的治疗中的用途。
背景技术
目前世界疼痛的发病率大约为35-45%,老年人的发病率更高,约为75%-90%,疼痛已是全球排位第三的治疗领域,市场巨大。阿片类药物是目前最强且常用的中枢镇痛药,过去的研究已经表明阿片类药物(如可待因、***、羟考酮、芬太尼)可有效止痛。它们与脑、脊髓以及胃肠道中的阿片受体结合从而减轻疼痛感。正是由于阿片类药物止痛效果显著,其滥用已经成为美国一个主要的公共健康问题;每天有78人因阿片类药物过量而死亡。因此临床上急需新靶点的强效镇痛药。
Sigma受体是独特的非阿片类受体,广泛分布于中枢神经***,Sigma1受体与所有主要中枢神经***疾病的病理生理学有关,包括情绪障碍(焦虑和抑郁)、精神病和精神***症,以及药物成瘾和疼痛。Sigma1受体拮抗剂还可增强阿片类镇痛剂的镇痛活性。本发明提供了一种新型结构的Sigma1受体拮抗剂。
发明内容
本发明提供了一种新的化合物,其具有Sigma1受体拮抗作用,在体外受体亲和力方面,对sigma1R的体外亲和力均强。同时在对D2L放射性配体结合分析及5HT-1A受体、CB1受体、CB2受体cAMP试验中,对这些受体亲和力均不佳,表现出较高的受体选择性。此外,在小鼠体内实验中,本发明提供的化合物还可增强阿片类镇痛剂的镇痛活性。
本发明提供了如式Ⅰ所示的化合物或式Ⅰ所示化合物的立体异构体、几何异构体、互变异构体、氮氧化合物、水合物、溶剂化合物、代谢产物、药学上可接受的盐或前药,
其中,R1选自氢、取代或未取代的C1-12烷基、取代或未取代的C3-12环烷基、取代或未取代的C2-12烯基、取代或未取代的C5-12芳基、取代或未取代的C5-12杂环基、取代或未取代的烷氧基、取代或未取代的烷硫基、取代或未取代的氨基或卤素;
R2和R3独立地选自氢、氘、取代或未取代的C1-12烷基、取代或未取代的C3-12环烷基、取代或未取代的C2-12烯基、取代或未取代的C5-10芳基、取代或未取代的C5-10杂环基,或者与它们相连的氮原子合起来形成取代或未取代的3元至15元杂环基基团。
进一步地,R1选自氢、取代或未取代的C1-12烷基、取代或未取代的C3-12环烷基、取代或未取代的C2-12烯基、取代或未取代的C5-12芳基、取代或未取代的C5-12杂环基、取代或未取代的烷氧基、取代或未取代的烷硫基、取代或未取代的氨基或卤素;
R2和R3独立地选自氢、氘、甲基、乙基、丙基、丁基、取代或未取代的芳甲基、取代或未取代的芳乙基、取代或未取代的芳杂甲基、取代或未取代的芳杂乙基,或R2和R3与它们相连的氮原子合起来形成取代或未取代的吗啉环基、取代或未取代的哌嗪环基、取代或未取代的吡咯烷基、取代或未取代的哌啶基、取代或未取代的六氢嘧啶基、取代或未取代的咪唑基、取代或未取代的硫代吗啉基、取代或未取代的氮杂环辛烷基、取代或未取代的氮杂环庚烷基;
其中,所述取代基选自一个或多个的氘、卤素、羟基、C1-C6烷基、C1-C6烷氧基、C1-C6烷硫基、胺基、C1-C6烷胺基、C1-C6烷酰胺基、C5-C10芳基、C5-C10芳烷基、C5-C10杂环基、NO2、CN、CF3,或者合起来它们形成稠环体系。
进一步地,其具有通式Ⅰ'所示结构:
R1分别选自氢、甲基、取代或未取代的环丙基、取代或未取代的环已基、取代或未取代的环戊基、取代或未取代的苯基、取代或未取代的吡啶基、取代或未取代的嘧啶基、取代或未取代的噻吩基、取代或未取代的噻唑基、取代或未取代的吡咯基、取代或未取代的呋喃环、取代或未取代的萘基、取代或未取代的喹啉基、取代或未取代的二苯并噻吩基、取代或未取代的丙基、取代或未取代的烯丙基、取代或未取代的苯并噻吩基、取代或未取代的呋喃基、取代或未取代的苯并呋喃基;
其中,所述取代基选自一个或多个的氘、卤素、羟基、甲基、乙基、环丙基、叔丁基、甲氧基、乙氧基、环丙氧基、叔丁氧基、甲硫基、乙硫基、环丙硫基、叔丁硫基、胺基、甲胺基、乙胺基、环丙胺基、叔丁胺基、甲酰胺基、乙酰胺基、环丙酰胺基、叔丁酰胺基、NO2、CN、CF3。
进一步地,R1选自氢、取代或未取代的苯基、取代或未取代的萘基、取代或未取代的联苯基、代或未取代的苯并噻吩基、取代或未取代的噻吩基、取代或未取代的喹啉基、取代或未取代的呋喃基、取代或未取代的苯并呋喃基、取代或未取代的吡啶基、取代或未取代的环已基;
其中,所述取代基选自一个或多个的氘、卤素、羟基、甲基、乙基、环丙基、叔丁基、甲氧基、乙氧基、环丙氧基、叔丁氧基、甲硫基、乙硫基、环丙硫基、叔丁硫基、胺基、甲胺基、乙胺基、环丙胺基、叔丁胺基、甲酰胺基、乙酰胺基、环丙酰胺基、叔丁酰胺基、NO2、CN、CF3。
进一步地,R1选自萘基、4-氟苯基、3,4-二氯苯基、3,5-二氟苯基、4-(三氟甲氧基)苯基、3-(三氟甲氧基)苯基、4-喹啉基、3-[1,1'-联苯]基、2-苯并[b]噻吩基、2-噻吩基、3-吡啶基、4-氟-2-甲基苯基、3,4-二氟苯基、4-甲氧基苯基、2-甲氧基苯基、2-甲硫基苯基、4-[1,1'-联苯]基、4-氰基苯基、4-氯-2-三氟甲氧基苯基、4-氟-2-甲氧基苯基、4-氯-2-甲氧基苯基、2,4-二氟苯基、4-氟-2-三氟甲氧基苯基、苯基、2-氯-4-氟苯基、2,4-双(三氟甲基)苯基、2-氯苯基、2-吡啶基、环已基、2,4-二氯苯基、3-喹啉基、3-苯并[b]噻吩基、3-噻吩基。
本发明所述的化合物,选自下列化合物或其药学上可接受的盐:
进一步地,本发明优选如下化合物或其药学上可接受的盐或其前药:
4-{2-{[6-(萘-2-基)吡嗪-2-基]氧基}乙基}吗啉;
4-{2-{[6-(4-氟苯基)吡嗪-2-基]氧基}乙基}吗啉;
4-{2-{[6-(3,4-二氯苯基)吡嗪-2-基]氧基}乙基}吗啉;
4-{2-{[6-(3,5-二氟苯基)吡嗪-2-基]氧基}乙基}吗啉;
4-{2-{[6-(4-(三氟甲氧基)苯基)吡嗪-2-基]氧基}乙基}吗啉;
4-{2-{[6-(3-(三氟甲氧基)苯基)吡嗪-2-基]氧基}乙基}吗啉;
4-{2-{[6-(喹啉-4-基)吡嗪-2-基]氧基}乙基}吗啉;
4-{2-{[6-([1,1'-联苯]-3-基)吡嗪-2-基]氧基}乙基}吗啉;
4-{2-{[6-(苯并[b]噻吩-2-基)吡嗪-2-基]氧基}乙基}吗啉;
4-{2-{[6-(噻吩-2-基)吡嗪-2-基]氧基}乙基}吗啉;
4-{2-{[6-(吡啶-3-基)吡嗪-2-基]氧基}乙基}吗啉;
4-{2-{[6-(4-氟-2-甲基苯基)吡嗪-2-基]氧基}乙基}吗啉。
进一步地,本发明化合物或其药学上可接受的盐、异构体中的氢可被一个或多个氘所取代。
本发明还提供了上述化合物的制备方法,所述方法包括如下步骤:
使如下式Ⅱ化合物和式VI化合物在DMF、DMSO、CH3CN或THF溶剂中,在K2CO3、Cs2CO3、CsF或NaH的碱性条件下在0-120℃发生取代反应,4-16小时后制得式Ⅴ化合物;
使所述式Ⅴ化合物继续在Na2CO3、K2CO3、Cs2CO3或CsF等碱性条件下与式Ⅲ所述的有机硼酸或式Ⅳ所述的有机硼酸酯在1,4-dioxane、DMF、DMSO、DME或1,4-dioxane/H2O等溶剂中,在Pd(PPh3)4、Pd(dppf)Cl2、Pd(PPh3)2Cl2、Pd(Cy3)2Cl2或Pd(OAc)2等催化剂催化下,80-160℃温度下反应8-16小时,制得式I化合物
本发明还提供了式Ⅰ、Ⅰ'的化合物的用途,在制备治疗或预防sigma受体介导的疾病或疾病状态的药物中的用途。
进一步地,本发明涉及式Ⅰ、Ⅰ'的化合物的用途,尤其是在制备治疗或预防腹泻,脂蛋白病症、偏头痛,肥胖症、关节炎、高血压、心律失常,溃疡、认知障碍、化学物质成瘾、迟发性椎间盘、缺血性中风、癫痫、中风、抑郁、压力、精神病、疼痛、疼痛增敏、癌症。尤其是神经性疼痛、炎性痛、异常性疼痛、癌痛、术后疼痛和/或痛觉过敏药物中的用途。
具体实施方式
以下将结合实施例和试验例对本发明作进一步的详细描述,本发明的实施例和试验例仅用于说明本发明的技术方案,并非对本发明的限制,凡依照本发明公开的内容所作的任何本领域的等同置换,均属于本发明的保护范围。
化合物的结构是核磁共振(1HNMR)或液质联用(LC-MS)来确定的。
液质联用仪(LC-MS)为安捷伦G6120B(与液相Agilent1260配用);核磁共振仪(1HNMR)为BrukerAVANCE-400或BrukerAVANCE-800,核磁共振(1HNMR)位移(δ)以百万分之一(ppm)的单位给出,测定溶剂为CDCl3,内标为四甲基硅烷(TMS),化学位移是以10-6(ppm)作为单位给出。
本发明的术语“室温”是指温度处于10~25℃之间。
实施例1:4-{2-{[6-(萘-2-基)吡嗪-2-基]氧基}乙基}吗啉的制备
步骤一,室温下,将化合物II(2.38g,10mmol),化合物Ⅵ(1.97g,15mmol),Cs2CO3(9.75g,30mmol)加入到DMF(30mL)中,加热到100℃,反应6h,原料反应完全。将反应液冷却到室温,加入H2O(30mL),用乙酸乙酯(50mL*3)萃取三次,有机相依次用水,饱和食盐水洗涤,有机相用无水硫酸钠干燥,过滤,滤液旋干,粗品用洗脱剂石油醚:乙酸乙酯=3:1过柱,旋干,真空干燥得到2.53g化合物V。收率:88.3%。
步骤二,室温下,将化合物Ⅴ(2.54g,8.8mmol),化合物萘-2-基硼酸(1.82g,10.6mmol),CsF(1.61g,10.6mmol)加入到1,4-dioxane/H2O(30mL,V/V=5/1)中,氮气置换后,再加入Pd(dppf)Cl2(0.64g,0.88mmol),再次氮气置换三次,氮气保护下加热到100℃,反应16h,原料反应完全。将反应液冷却到室温,加入H2O(30mL),用乙酸乙酯(50mL*3)萃取三次,有机相依次用水,饱和食盐水洗涤,有机相用无水硫酸钠干燥,过滤,滤液旋干,粗品用洗脱剂石油醚:乙酸乙酯=2:1过柱,旋干,真空干燥得到2.45g的4-{2-{[6-(萘-2-基)吡嗪-2-基]氧基}乙基}吗啉。收率:83.1%,纯度为99.48%。
ESI-MS:m/z=336.2(M+H)+。
1H NMR(400MHz,CDCl3)δ8.74(s,1H),8.50(s,1H),8.21(s,1H),8.12(dd,J=8.6,1.7Hz,1H),7.96(dd,J=8.5,5.1Hz,2H),7.88(dq,J=6.9,3.3Hz,1H),7.58–7.50(m,2H),4.66(t,J=5.8Hz,2H),3.80–3.73(m,4H),2.89(t,J=5.8Hz,2H),2.70–2.54(m,4H)。
实施例2:4-{2-{[6-(4-氟苯基)吡嗪-2-基]氧基}乙基}吗啉的制备
按实施例1的制备方法,将步骤二中的2-萘硼酸换成等摩尔量的4-氟苯硼酸,得到标题化合物,收率:82.7%,纯度为99.69%。
ESI-MS:m/z=304.2(M+H)+。
1H NMR(400MHz,CDCl3)δ8.55(s,1H),8.17(s,1H),8.06–7.95(m,2H),7.22–7.13(m,2H),4.59(t,J=5.8Hz,2H),3.78–3.73(m,4H),2.85(t,J=5.8Hz,2H),2.69–2.49(m,4H)。
实施例3:4-{2-{[6-(3,4-二氯苯基)吡嗪-2-基]氧基}乙基}吗啉的制备
按实施例1的制备方法,将步骤二中的2-萘硼酸换成等摩尔量的3,4-二氯苯硼酸,得到标题化合物,收率:83.2%,纯度为99.41%。
ESI-MS:m/z=354.2(M+H)+。
1H NMR(400MHz,CDCl3)δ8.57(s,1H),8.22(s,1H),8.12(d,J=2.0Hz,1H),7.83(dd,J=8.4,2.0Hz,1H),7.56(d,J=8.4Hz,1H),4.59(t,J=5.8Hz,2H),3.78–3.73(m,4H),2.86(t,J=5.8Hz,2H),2.67–2.52(m,4H)。
实施例4:4-{2-{[6-(3,5-二氟苯基)吡嗪-2-基]氧基}乙基}吗啉的制备
按实施例1的制备方法,将步骤二中的2-萘硼酸换成等摩尔量的3,5-二氟苯硼酸,得到标题化合物,收率:82.4%,纯度为99.79%。
ESI-MS:m/z=322.2(M+H)+。
1H NMR(400MHz,CDCl3)δ8.56(s,1H),8.24(s,1H),7.59–7.50(m,2H),6.94–6.85(m,1H),4.59(t,J=5.8Hz,2H),3.78–3.73(m,4H),2.86(t,J=5.8Hz,2H),2.66–2.53(m,4H)。
实施例5:4-{2-{[6-(4-(三氟甲氧基)苯基)吡嗪-2-基]氧基}乙基}吗啉的制备
按实施例1的制备方法,将步骤二中的2-萘硼酸换成等摩尔量的4-(三氟甲氧基)苯硼酸,得到标题化合物,收率:81.8%,纯度为99.78%。
ESI-MS:m/z=370.2(M+H)+。
1H NMR(400MHz,CDCl3)δ8.58(s,1H),8.21(s,1H),8.08–8.00(m,2H),7.33(d,J=8.4Hz,2H),4.59(t,J=5.8Hz,2H),3.79–3.73(m,4H),2.86(t,J=5.8Hz,2H),2.66–2.52(m,4H)。
实施例6:4-{2-{[6-(3-(三氟甲氧基)苯基)吡嗪-2-基]氧基}乙基}吗啉的制备
按实施例1的制备方法,将步骤二中的2-萘硼酸换成等摩尔量的3-(三氟甲氧基)苯硼酸,得到标题化合物,收率:80.2%,纯度为99.28%。
ESI-MS:m/z=370.2(M+H)+。
1H NMR(400MHz,CDCl3)δ8.60(s,1H),8.23(s,1H),7.96–7.87(m,2H),7.52(t,J=8.0Hz,1H),7.31(d,J=8.2Hz,1H),4.61(t,J=5.8Hz,2H),3.82–3.72(m,4H),2.86(t,J=5.8Hz,2H),2.67–2.54(m,4H)。
实施例7:4-{2-{[6-(喹啉-4-基)吡嗪-2-基]氧基}乙基}吗啉的制备
按实施例1的制备方法,将步骤二中的2-萘硼酸换成等摩尔量的4-喹啉硼酸,得到标题化合物,收率:82.9%,纯度为99.25%。
ESI-MS:m/z=337.2(M+H)+。
1H NMR(400MHz,CDCl3)δ9.34(s,1H),8.69(s,1H),8.48(s,1H),8.34(s,1H),8.23(d,J=8.4Hz,1H),8.09(d,J=8.1Hz,1H),7.79–7.73(m,1H),7.69(t,J=7.2Hz,1H),4.55(t,J=5.7Hz,2H),3.74–3.71(m,4H),2.84(t,J=5.7Hz,2H),2.61–2.52(m,4H)。
实施例8:4-{2-{[6-([1,1'-联苯]-3-基)吡嗪-2-基]氧基}乙基}吗啉的制备
按实施例1的制备方法,将步骤二中的2-萘硼酸换成等摩尔量的3-[1,1'-联苯]硼酸,得到标题化合物,收率:82.5%,纯度为99.74%。
ESI-MS:m/z=362.2(M+H)+。
1H NMR(400MHz,CDCl3)δ8.66(s,1H),8.23–8.19(m,2H),7.98(d,J=7.8Hz,1H),7.70–7.63(m,3H),7.56(t,J=7.7Hz,1H),7.51–7.45(m,2H),7.40(t,J=7.3Hz,1H),4.62(t,J=5.8Hz,2H),3.76–3.72(m,4H),2.86(t,J=5.8Hz,2H),2.66–2.55(m,4H)。
实施例9:4-{2-{[6-(苯并[b]噻吩-2-基)吡嗪-2-基]氧基}乙基}吗啉的制备
按实施例1的制备方法,将步骤二中的2-萘硼酸换成等摩尔量的2-苯并[b]噻吩硼酸,得到标题化合物,收率:81.9%,纯度为99.99%。
ESI-MS:m/z=342.2(M+H)+。
1H NMR(400MHz,CDCl3)δ8.58(s,1H),8.52–8.47(m,1H),8.22(s,1H),7.96–7.89(m,2H),7.50–7.40(m,2H),4.61(t,J=5.7Hz,2H),3.77–3.73(m,4H),2.87(t,J=5.7Hz,2H),2.65–2.53(m,4H)。
实施例10:4-{2-{[6-(噻吩-2-基)吡嗪-2-基]氧基}乙基}吗啉的制备
按实施例1的制备方法,将步骤二中的2-萘硼酸换成等摩尔量的2-噻吩硼酸,得到标题化合物,收率:81.7%,纯度为99.85%。
ESI-MS:m/z=292.2(M+H)+。
1H NMR(400MHz,CDCl3)δ8.50(s,1H),8.08(s,1H),7.65(d,J=3.6Hz,1H),7.44(d,J=4.9Hz,1H),7.14(dd,J=4.8,3.9Hz,1H),4.57(t,J=5.8Hz,2H),3.77–3.72(m,4H),2.84(t,J=5.8Hz,2H),2.64–2.55(m,4H)。
实施例11:4-{2-{[6-(吡啶-3-基)吡嗪-2-基]氧基}乙基}吗啉的制备
按实施例1的制备方法,将步骤二中的2-萘硼酸换成等摩尔量的3-吡啶硼酸,得到标题化合物,收率:82.5%,纯度为99.71%。
ESI-MS:m/z=287.2(M+H)+。
1H NMR(400MHz,CDCl3)δ9.25(d,J=2.0Hz,1H),8.69(dd,J=4.8,1.4Hz,1H),8.62(s,1H),8.32–8.27(m,1H),8.25(s,1H),7.43(dd,J=8.0,4.8Hz,1H),4.60(t,J=5.8Hz,2H),3.79–3.73(m,4H),2.86(t,J=5.8Hz,2H),2.67–2.53(m,4H)。
实施例12:4-{2-{[6-(4-氟-2-甲基苯基)吡嗪-2-基]氧基}乙基}吗啉的制备
按实施例1的制备方法,将步骤二中的2-萘硼酸换成等摩尔量的(4-氟-2-甲基)苯硼酸,得到标题化合物,收率:81.2%,纯度为99.99%。
ESI-MS:m/z=292.2(M+H)+。
1H NMR(400MHz,CDCl3)δ8.22(d,J=13.6Hz,2H),7.41(dd,J=8.3,5.9Hz,1H),7.05–6.95(m,2H),4.50(t,J=5.7Hz,2H),3.77–3.71(m,4H),2.82(t,J=5.7Hz,2H),2.62–2.50(m,4H),2.43(s,3H)。
试验例1:sigma1体外亲和力测试
1.材料及设备
2.试验用溶液的配制
体外受体结合试验需要下列溶液,其中A液做为母液,B液用于制备sigma1受体膜。
A液:将6.05g Tris溶于1000mL双蒸水中,用浓盐酸将体系pH调至7.4,然后稀释到4000mL,最终得到0.05M的Tris-HCl缓冲液。
B液0.05M的Tris-HCl缓冲液,含0.32M的蔗糖。
所有测试的化合物都预先配制成受试母液。分别称取适量的受试化合物,用少量DMSO溶解,然后用两次蒸馏水配制成10-5M浓度,于4℃冰箱中保存。
3.试验操作
3.1sigma1受体膜的制备
豚鼠断头,冰上操作,迅速取大脑皮层,将组织合到一根离心管中。在离心管中加入适量B液(0.05M Tris-HCl,w/0.32M蔗糖),用匀浆机的4档进行组织匀浆,每次3-4秒,匀浆4次。匀浆后加入提取液,将其调整为10mL/g,用天平调整离心管重量,经高速冷冻离心机于1000rpm离心10分钟;离心后取上层液加B液调整为2mL/g,于1000rpm、4℃离心10分钟;取上清液,11500rpm,4℃离心25分钟;取沉淀加B液调整为3mL/g,在恒温水温箱中于25℃孵育15分钟。孵育完毕,于11500rpm,4℃离心25分钟,将沉淀于-80℃储存备用。
3.2试验方法
1)在制备好的膜中加入用适量匀浆液,用匀浆机分散成混悬液;并检测蛋白浓度(4mg/mL);
2)向96孔板中分别加入100μg蛋白,体积是90μL;
3)测试孔加入1μL的化合物(最高终浓度为1μM,四倍稀释,8个浓度),ZPE孔中加入1uL A液,HPE加入1uL的haloperidol(终浓度为1μM);
4)各孔中加入10μL的[3H]-(+)-pentazocine(终浓度为10nM);
5)将96孔板置于恒温水浴箱中孵育(25℃,180分钟);孵育完毕后,96孔内混悬液用提前在0.25%PEI溶液中准备好的GF/C板减压快速过滤,过滤后GF/C用A液淋洗三次;洗后置于37℃烘箱中烘干;
6)向GF/C板中加入闪烁液50μL/孔;
7)将GF/C放入液闪计数仪中,按程序操作,读取试验数值。
4.试验结果
表1:
如表1所示,本发明实施例1、2、3、4、5、6、12化合物对sigma1R的体外亲和力强。
试验例2:其它靶点体外亲和力测试
为了评估实施例化合物的靶点选择性,我们通过D2L放射性配体结合分析及5HT-1A受体、CB1受体、CB2受体cAMP试验,测定实施例化合物对它们的体外活性。
1.D2L放射性配体结合分析
1.1试验试剂
1.2试验仪器
1.3试剂配制
分析缓冲液:50mM Tris-HCl pH 7.4,10mM MgCl2,1mM EDTA,120mM NaCl
洗涤缓冲液:50mM Tris-HCl pH 7.4,4℃储存
0.5%PEI溶液:0.5mL PEI溶于100mL ddH2O中,4℃储存。
1.4 D2L膜蛋白的提取
1)用胰蛋白酶消化D2L细胞,然后收集D2L细胞。
2)向LDL细胞中加入10倍体积的预冷0.32M蔗糖(每100mL含1片蛋白酶抑制剂丸),用高速分散器将其分解。
3)将匀浆在900g,4℃下离心10min。收集上清液。
4)将上清液在40000g,4℃下离心60min,弃上清。
5)用预冷PBS(每100mL含有1片蛋白酶抑制剂丸)重悬沉淀。将重悬浮液转移至50mL均化器中进行均质化。
6)在40000g,4℃下离心匀浆10分钟,弃去上清液。
7)重复洗涤程序三次。
8)用4体积PBS重悬最终沉淀,液氮处理-80℃保存。
1.5试验方法
1)在96孔深板中加入5uL cpds(1%DMSO)和100μL测定缓冲液。
2)每孔加入10uL膜和300uL测定缓冲液。
3)将[3H]-甲基螺哌隆(fianl浓度0.5nM)加入100μL测定缓冲液中,在27℃下孵育30分钟。
4)将UNIFILTER-96GF/B滤板与0.5%PEI预孵育1小时。
5)用1mL洗涤缓冲液/孔洗涤UNIFILTER-96GF/B滤板两次,将膜混合物转移到UNIFILTER-96GF/B滤板中,洗涤4次。
6)将板在55℃孵育10分钟。
7)每孔加入40μL ULTIMA GOLD,读取TopCount的CPM。
2.实施例化合物在5-HT1A受体cAMP试验中活性测试
2.1试验试剂耗材
2.2试验仪器设备
2.3试验方法
2.3.1细胞培养及试剂配制
(1)细胞株:Flp-In-CHO-5HT-1A
(2)完全培养基:Ham's F12K+10%胎牛血清+1*青霉素链霉素+800μg/mL潮霉素
(3)细胞接种培养基:Ham's F12K+10%DFBS
(4)试验缓冲液:1*HBSS+20mM HEPES+0.1%BSA+500μM IBMX
2.3.2待测化合物对5HT-1A受体激动剂活性测定
(1)细胞培养和种板
1)将Flp-In-CHO-5HT-1A细胞株培养于37℃,5%CO2环境下的完全培养基中;
2)TrypLE消化处理后将细胞重悬于接种培养基中,接种于60mm培养皿,接种密度为1*106,于37℃,5%CO2培养过夜。
(2)转染细胞
1)将转染试剂放置室温平衡。
2)混合Gi3和转染试剂,室温放置10分钟。
3)将配好的质粒加入到细胞培养皿中(见步骤2.3.1)。
4)细胞于37℃,5%CO2培养5-6小时。
(3)细胞铺板
1)将转染好的细胞接用接种培养基重悬,种到384细胞培养板中,接种密度为8000每孔。
2)细胞于37℃,5%CO2培养过夜。
(4)检测
1)准备试验缓冲液:1*HBSS,0.1%BSA,5mM HEPES及500μM IBMX。
2)将化合物用缓冲液稀释。
3)去掉384板子中的培养基,每孔加入15μL的缓冲液。
4)每孔加入2.5μL的化合物,37℃培养5分钟。
5)用试验缓冲液将forskolin稀释至8μM(8*)。
6)加入2.5μL步骤5中稀释好的8*forskolin,于37℃孵育10分钟。
7)冻融cAMP-d2和Anti-cAMP-Eu3+,用分析缓冲液将其稀释20倍。
8)加入10μL cAMP-d2至试验孔,然后加入10μL Anti-cAMP-Eu3+至试验孔中。
9)将反应板于室温200g离心30s,25℃静置1h后,利用Envision收集数据。
2.4数据分析
1)Z’factor=1-3*(SDMax+SDMin)/(MeanMax-MeanMin);
2)CVMax=(SDMax/MeanMax)*100%;
3)CVMin=(SDMin/MeanMin)*100%;
4)S/B=Singal/Background;
5)利用GraphPad非线性拟合公式计算化合物EC50/IC50:
Y=Bottom+(Top-Bottom)/(1+10^((LogEC50-X)*HillSlope))
Y=Bottom+(Top-Bottom)/(1+10^((LogIC50-X)*HillSlope))
X:化合物浓度log值;Y:Activation%or Inhibition%
3.在CB1受体及CB2受体cAMP试验中活性测试
3.1试验试剂耗材
3.2试验仪器设备
3.3试验方法
3.3.1细胞培养及试剂配制
1)细胞株:Flp-In-CHO-CB1和Flp-In-CHO-CB2
2)完全培养基:Ham's F12K+10%胎牛血清+1*青霉素链霉素+800μg/mL潮霉素
3)试验缓冲液:1*HBSS+20mM HEPES+0.1%BSA+500μM IBMX
3.3.2待测化合物对CB1和CB2受体活性测定
(1)细胞培养和种板
1)将Flp-In-CHO-CB1和Flp-In-CHO-CB2细胞株培养于37℃,5%CO2环境下的完全培养基中;
2)TrypLE消化处理后将细胞重悬于完全培养基中,种到384细胞培养板中,接种密度8000每孔。
3)细胞于37℃,5%CO2培养过夜。
(2)激动活性的检测
1)准备试验缓冲液:1*HBSS,0.1%BSA,20mM HEPES及500μM IBMX。
2)将化合物用缓冲液稀释。
3)去掉384板子中的培养基,每孔加入15μL的缓冲液。
4)每孔加入2.5μL的化合物,37℃培养10分钟。
5)用试验缓冲液将forskolin稀释至8μM(8*)。
6)加入2.5μL稀释好的8*forskolin,于37℃孵育30分钟。
7)冻融Eu-cAMP tracer和Ulight-anti-cAMP,用cAMP检测缓冲液稀释。
8)加入10μL Eu-cAMP tracer至试验孔,然后加入10μL Ulight-anti-cAMP至试验孔中。
9)将反应板于室温200g离心30s,25℃静置1h后,利用Envision收集数据。
3.4数据分析
1)Z’factor=1-3*(SDMax+SDMin)/(MeanMax-MeanMin);
2)CVMax=(SDMax/MeanMax)*100%;
3)CVMin=(SDMin/MeanMin)*100%;
4)S/B=Singal/Background;
5)利用GraphPad非线性拟合公式计算化合物EC50/IC50:
Y=Bottom+(Top-Bottom)/(1+10^((LogEC50-X)*HillSlope))
Y=Bottom+(Top-Bottom)/(1+10^((LogIC50-X)*HillSlope))
X:化合物浓度log值;Y:Activation%or Inhibition%。
4.对D2L的放射性配体结合分析测试结果及对5HT-1A、CB1、CB2受体的CAMP试验中的活性测试结果
实施例化合物对其它靶点的体外活性如表2所示,实施例3、5、6对D2L的放射性配体结合分析所测得的体外亲和力IC50及对5HT-1A、CB1、CB2受体的CAMP试验中的体外激动活性EC50均大于1μM。
表2:其它靶点体外活性测试结果
试验例3:镇痛增敏作用测试(热水缩尾试验和压爪试验)
1试验动物
1.1基本信息
种属:Balb/C,等级:SPF,预定购入小鼠数量和性别:80只,全雄性;纳入正式试验的动物数量和性别:60只,全雄性;年龄:8W周龄;体重:体重均数在25-30g的范围内,体重个体值应在均数±20%范围内;入室后环境适应期:入室试验前先适应环境5天,并观察是否出现异常;适应期主要检查内容:动物一般状态及体重。
1.2小鼠分组
组别设计:热水缩尾试验随机分为3组;压爪试验随机分为3组
小鼠数量:使用80只,其中20只用于预试(数据不计入正式试验);
2主要仪器
压爪仪(型号37215,Ugo-Basile,瓦雷泽,意大利);水浴锅,温度计
3试验方法
3.1热水缩尾试验(Tail immersion test)评估药物对热痛的影响
试验小鼠随机分为3个组:单独注射***组,***+生理盐水,***+实施例1,每组10只动物。
给药方式:首先在试验小鼠的肩胛区域皮下注射***(3mg/kg,5mL/kg),15min后,腹腔注射实施例1(40mg/kg,10mL/kg),30min后进行试验。将水浴锅水温设置为52℃,试验小鼠被放入改装后的50mL离心管内,其尾部自然垂落,试验时将动物尾尖以上3cm置于52℃水中,当尾巴扭动、甩出水面时记录该延迟时间,每次试验重复2次。为了防止烫伤动物,将截断时间阈值设为15s。镇痛率(%)=[(测定值-基线值)/基线值]×100。
3.2压爪试验(Paw pressure test)评估药物对机械疼痛的影响
试验小鼠随机分为3个组:单独注射***组,***+生理盐水,***+实施例1,每组10只动物。
给药方式:首先在试验小鼠的肩胛区域皮下注射***(4mg/kg,5mL/kg),5min后,再在其肩胛另一区域皮下注射实施例1(64mg/kg,5mL/kg)或者等剂量的实施例1,25min后进行压爪试验。将压爪仪的压力调整为恒定的450g,用圆剑尖刺激试验动物脚掌,当动物出现挣扎立即停止刺激,并记录相应的延迟时间。每次试验重复2~3次,每次刺激间隔1min,为了保护动物脚掌不被压伤,将截断时间阈值设置为50s。镇痛率(%)=[(测定值-基线值)/基线值]×100。
4试验结果
4.1实施例1对***在热痛镇痛中的影响
试验结果表明,低剂量***(3mg/kg)对热痛的镇痛率较低(35.43%),当实施例1与***联合使用后,***的镇痛作用有显著增强(155.7%,p<0.005)。如下表3所示:
表3:
4.2实施例1对***在机械痛镇痛中的影响
试验结果显示,低剂量的***(4mg/kg)能够将动物的机械疼痛减少66.09%;当低剂量***与实施例1联合用药后,***的镇痛作用有了更为显著的提高(279.15%,p<0.05),可见实施例1对***都有很强的增敏作用。如下表4所示:
表4:
5结论
通过热水缩尾试验和压爪试验,发现***在实施例1联合使用后,在热痛和机械痛中的镇痛作用均得到了明显增强。
试验例4:对阿片激动剂TRV130的增效作用(热板镇痛试验)
1试验试剂
2试验仪器
1mL注射器、计时器、微量移液器、电子天平、15mL离心管、50mL离心管、热板仪等。
3试验动物
KM小鼠,全雌,体重20-25g,由成都达硕生物科技有限公司提供。
4试验方法
4.1供试品配制
称取TRV130化合物约6mg于50mL离心管中,加入60μL的50%HS-15震荡溶解后加入生理盐水配制成0.3mg/mL的供试品溶液。称取实施例化合物约16mg于15mL离心管中,加入160μL的50%HS-15震荡溶解后加入生理盐水配制成4mg/mL的供试品溶液。难溶化合物可加热助溶。
4.2给药及检测
适应期过后,在给药前一天对小鼠进行痛阈的测定。将20g左右的雌鼠放在预热至50-55℃金属板上,恒温(变化在±0.5℃内),以小鼠舔后足反应的潜伏期为痛阈指标。试验前筛选动物,潜伏期在5-30s之间的动物合格,剔除过于敏感、反应迟钝和跳跃反应的试验动物。合格小鼠于次日进行正式药效试验。为了防止烫伤动物,将截止时间阈值设置为60s。每只动物测定2次取平均值,每次测定阈值时应间隔5min以上。根据基础痛阈选取32只动物随机分成4组,每组8只:按下表5进行给药。
表5:
腹腔给药5min后第二次给药:
根据上述表格进行给药,分别在第一次给药后的30、60、120min测试给药后的痛阈,考察实施例化合物对TRV130的镇痛增敏作用。
5试验结果
根据如下公式计算药物的痛阈提高率:
本次试验完成了实施例三个化合物的小鼠热板法镇痛试验。试验结果如下:
实施例系列化合物热板试验结果如下表6所示:实施例3、实施例5、实施例6化合物具有较强的镇痛增敏作用。
表6:
Claims (10)
1.一种化合物,其为如式Ⅰ所示的化合物或式Ⅰ所示化合物的立体异构体、几何异构体、互变异构体、氮氧化合物、水合物、溶剂化合物、代谢产物、药学上可接受的盐或前药,
其中,R1选自氢、取代或未取代的C1-12烷基、取代或未取代的C3-12环烷基、取代或未取代的C2-12烯基、取代或未取代的C5-12芳基、取代或未取代的C5-12杂环基、取代或未取代的烷氧基、取代或未取代的烷硫基、取代或未取代的氨基或卤素;
R2和R3独立地选自氢、氘、取代或未取代的C1-12烷基、取代或未取代的C3-12环烷基、取代或未取代的C2-12烯基、取代或未取代的C5-10芳基、取代或未取代的C5-10杂环基,或者与它们相连的氮原子合起来形成取代或未取代的3元至15元杂环基基团。
2.如权利要求1所述的化合物、或其立体异构体或互变异构体、或其药学上可接受的盐、水合物、溶剂化物或前药,其特征在于,
R1选自氢、取代或未取代的C1-12烷基、取代或未取代的C3-12环烷基、取代或未取代的C2-12烯基、取代或未取代的C5-12芳基、取代或未取代的C5-12杂环基、取代或未取代的烷氧基、取代或未取代的烷硫基、取代或未取代的氨基或卤素;
R2和R3独立地选自氢、氘、甲基、乙基、丙基、丁基、取代或未取代的芳甲基、取代或未取代的芳乙基、取代或未取代的芳杂甲基、取代或未取代的芳杂乙基,或R2和R3与它们相连的氮原子合起来形成取代或未取代的吗啉环基、取代或未取代的哌嗪环基、取代或未取代的吡咯烷基、取代或未取代的哌啶基、取代或未取代的六氢嘧啶基、取代或未取代的咪唑基、取代或未取代的硫代吗啉基、取代或未取代的氮杂环辛烷基、取代或未取代的氮杂环庚烷基;
其中,所述取代基选自一个或多个的氘、卤素、羟基、C1-C6烷基、C1-C6烷氧基、C1-C6烷硫基、胺基、C1-C6烷胺基、C1-C6烷酰胺基、C5-C10芳基、C5-C10芳烷基、C5-C10杂环基、NO2、CN、CF3,或者合起来它们形成稠环体系。
3.如权利要求2所述的化合物、或其立体异构体或互变异构体、或其药学上可接受的盐、水合物、溶剂化物或前药,其特征在于,具有通式Ⅰ'所示结构:
R1分别选自氢、甲基、取代或未取代的环丙基、取代或未取代的环已基、取代或未取代的环戊基、取代或未取代的苯基、取代或未取代的吡啶基、取代或未取代的嘧啶基、取代或未取代的噻吩基、取代或未取代的噻唑基、取代或未取代的吡咯基、取代或未取代的呋喃环、取代或未取代的萘基、取代或未取代的喹啉基、取代或未取代的二苯并噻吩基、取代或未取代的丙基、取代或未取代的烯丙基、取代或未取代的苯并噻吩基、取代或未取代的呋喃基、取代或未取代的苯并呋喃基;
其中,所述取代基选自一个或多个的氘、卤素、羟基、甲基、乙基、环丙基、叔丁基、甲氧基、乙氧基、环丙氧基、叔丁氧基、甲硫基、乙硫基、环丙硫基、叔丁硫基、胺基、甲胺基、乙胺基、环丙胺基、叔丁胺基、甲酰胺基、乙酰胺基、环丙酰胺基、叔丁酰胺基、NO2、CN、CF3。
4.如权利要求1-3所述的化合物、其立体异构体或互变异构体、或其药学上可接受的盐、水合物、溶剂化物或前药,其特征在于:
R1选自氢、取代或未取代的苯基、取代或未取代的萘基、取代或未取代的联苯基、代或未取代的苯并噻吩基、取代或未取代的噻吩基、取代或未取代的喹啉基、取代或未取代的呋喃基、取代或未取代的苯并呋喃基、取代或未取代的吡啶基、取代或未取代的环已基;
其中,所述取代基选自一个或多个的氘、卤素、羟基、甲基、乙基、环丙基、叔丁基、甲氧基、乙氧基、环丙氧基、叔丁氧基、甲硫基、乙硫基、环丙硫基、叔丁硫基、胺基、甲胺基、乙胺基、环丙胺基、叔丁胺基、甲酰胺基、乙酰胺基、环丙酰胺基、叔丁酰胺基、NO2、CN、CF3。
5.如权利要求1-4所述的化合物、或其立体异构体或互变异构体、或其药学上可接受的盐、水合物、溶剂化物或前药,其特征在于:
R1选自萘基、4-氟苯基、3,4-二氯苯基、3,5-二氟苯基、4-(三氟甲氧基)苯基、3-(三氟甲氧基)苯基、4-喹啉基、3-[1,1'-联苯]基、2-苯并[b]噻吩基、2-噻吩基、3-吡啶基、4-氟-2-甲基苯基、3,4-二氟苯基、4-甲氧基苯基、2-甲氧基苯基、2-甲硫基苯基、4-[1,1'-联苯]基、4-氰基苯基、4-氯-2-三氟甲氧基苯基、4-氟-2-甲氧基苯基、4-氯-2-甲氧基苯基、2,4-二氟苯基、4-氟-2-三氟甲氧基苯基、苯基、2-氯-4-氟苯基、2,4-双(三氟甲基)苯基、2-氯苯基、2-吡啶基、环已基、2,4-二氯苯基、3-喹啉基、3-苯并[b]噻吩基、3-噻吩基。
7.如权利要求1所述的化合物,选自下列化合物或其药学上可接受的盐或其前药:
4-{2-{[6-(萘-2-基)吡嗪-2-基]氧基}乙基}吗啉;
4-{2-{[6-(4-氟苯基)吡嗪-2-基]氧基}乙基}吗啉;
4-{2-{[6-(3,4-二氯苯基)吡嗪-2-基]氧基}乙基}吗啉;
4-{2-{[6-(3,5-二氟苯基)吡嗪-2-基]氧基}乙基}吗啉;
4-{2-{[6-(4-(三氟甲氧基)苯基)吡嗪-2-基]氧基}乙基}吗啉;
4-{2-{[6-(3-(三氟甲氧基)苯基)吡嗪-2-基]氧基}乙基}吗啉;
4-{2-{[6-(喹啉-4-基)吡嗪-2-基]氧基}乙基}吗啉;
4-{2-{[6-([1,1'-联苯]-3-基)吡嗪-2-基]氧基}乙基}吗啉;
4-{2-{[6-(苯并[b]噻吩-2-基)吡嗪-2-基]氧基}乙基}吗啉;
4-{2-{[6-(噻吩-2-基)吡嗪-2-基]氧基}乙基}吗啉;
4-{2-{[6-(吡啶-3-基)吡嗪-2-基]氧基}乙基}吗啉;
4-{2-{[6-(4-氟-2-甲基苯基)吡嗪-2-基]氧基}乙基}吗啉。
8.如权利要求1-7所述的化合物或其药学上可接受的盐、异构体,其特征在于,所述化合物中的氢可被一个或多个氘所取代。
9.制备权利要求1-7所述的化合物或其异构体、关键中间体的方法,其特征在于,所述方法包括如下步骤:
使如下式Ⅱ化合物和式VI化合物在DMF、DMSO、CH3CN或THF溶剂中,在K2CO3、Cs2CO3、CsF或NaH的碱性条件下在0-120℃发生取代反应,4-16小时后制得式Ⅴ化合物;
使所述式Ⅴ化合物继续在Na2CO3、K2CO3、Cs2CO3或CsF等碱性条件下与式Ⅲ所述的有机硼酸或式Ⅳ所述的有机硼酸酯在1,4-dioxane、DMF、DMSO、DME或1,4-dioxane/H2O等溶剂中,在Pd(PPh3)4、Pd(dppf)Cl2、Pd(PPh3)2Cl2、Pd(Cy3)2Cl2或Pd(OAc)2等催化剂催化下,80-160℃温度下反应8-16小时,制得式I化合物;
10.权利要求1-8所述的化合物,在制备治疗或预防sigma受体介导的疾病或疾病状态药物中的用途。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910736071 | 2019-08-09 | ||
CN2019107360710 | 2019-08-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112341397A true CN112341397A (zh) | 2021-02-09 |
CN112341397B CN112341397B (zh) | 2023-05-23 |
Family
ID=74357586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010772942.7A Active CN112341397B (zh) | 2019-08-09 | 2020-08-04 | 吡嗪类衍生物或盐、异构体、其制备方法及用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112341397B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115677611A (zh) * | 2021-07-22 | 2023-02-03 | 成都苑东生物制药股份有限公司 | 2H-苯并[b][1,4]恶嗪-3(4H)-酮衍生物 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1520404A (zh) * | 2000-11-20 | 2004-08-11 | �Ȱ�ά����ķ�ɷݹ�˾ | 作为五羟色胺5-ht2受体拮抗剂的哌嗪基吡嗪化合物 |
US20080125416A1 (en) * | 2004-08-27 | 2008-05-29 | Christian Laggner | Sigma Receptor Inhibitors |
CN101468965A (zh) * | 2003-03-24 | 2009-07-01 | 默克公司 | 联芳基取代的6元杂环钠通道阻滞剂 |
CN102066334A (zh) * | 2008-04-25 | 2011-05-18 | 埃斯蒂维实验室股份有限公司 | 增强阿片样物质的镇痛作用和减弱其依赖性的作为σ配体的1-芳基-3-氨基烷氧基-吡唑 |
CN102188708A (zh) * | 2004-06-04 | 2011-09-21 | 麦兰实验室公司 | 含奈必洛尔的组合物 |
US20120289508A1 (en) * | 2010-02-04 | 2012-11-15 | Vela Hernandez Jose Miguel | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
US20130324535A1 (en) * | 2010-12-03 | 2013-12-05 | Laboratorios Del Dr. Esteve, S.A. | Use of sigma ligands in bone cancer pain |
US20170182010A1 (en) * | 2014-05-12 | 2017-06-29 | Fondazione Istituto Italiano Di Techologia | Benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments |
CN109562137A (zh) * | 2015-09-01 | 2019-04-02 | 第波生物公司 | 用于治疗与异常炎性反应有关的病况的方法和组合物 |
CN112341404A (zh) * | 2019-08-09 | 2021-02-09 | 成都苑东生物制药股份有限公司 | 新型噻唑类衍生物或盐、异构体、其制备方法及用途 |
CN113024435A (zh) * | 2019-12-09 | 2021-06-25 | 苏州恩华生物医药科技有限公司 | 连双环结构sigma-1受体抑制剂 |
-
2020
- 2020-08-04 CN CN202010772942.7A patent/CN112341397B/zh active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1520404A (zh) * | 2000-11-20 | 2004-08-11 | �Ȱ�ά����ķ�ɷݹ�˾ | 作为五羟色胺5-ht2受体拮抗剂的哌嗪基吡嗪化合物 |
CN101468965A (zh) * | 2003-03-24 | 2009-07-01 | 默克公司 | 联芳基取代的6元杂环钠通道阻滞剂 |
CN102188708A (zh) * | 2004-06-04 | 2011-09-21 | 麦兰实验室公司 | 含奈必洛尔的组合物 |
US20080125416A1 (en) * | 2004-08-27 | 2008-05-29 | Christian Laggner | Sigma Receptor Inhibitors |
CN102066334A (zh) * | 2008-04-25 | 2011-05-18 | 埃斯蒂维实验室股份有限公司 | 增强阿片样物质的镇痛作用和减弱其依赖性的作为σ配体的1-芳基-3-氨基烷氧基-吡唑 |
US20120289508A1 (en) * | 2010-02-04 | 2012-11-15 | Vela Hernandez Jose Miguel | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
US20130324535A1 (en) * | 2010-12-03 | 2013-12-05 | Laboratorios Del Dr. Esteve, S.A. | Use of sigma ligands in bone cancer pain |
US20170182010A1 (en) * | 2014-05-12 | 2017-06-29 | Fondazione Istituto Italiano Di Techologia | Benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments |
CN109562137A (zh) * | 2015-09-01 | 2019-04-02 | 第波生物公司 | 用于治疗与异常炎性反应有关的病况的方法和组合物 |
CN112341404A (zh) * | 2019-08-09 | 2021-02-09 | 成都苑东生物制药股份有限公司 | 新型噻唑类衍生物或盐、异构体、其制备方法及用途 |
CN113024435A (zh) * | 2019-12-09 | 2021-06-25 | 苏州恩华生物医药科技有限公司 | 连双环结构sigma-1受体抑制剂 |
Non-Patent Citations (2)
Title |
---|
JINHO LEE,等: "Synthesis and Evaluation of 5-(3-(Pyrazin-2-yl)benzylidene)thiazolidine-2,4-dione Derivatives as Pan–Pim Kinases Inhibitors", CHEMICAL AND PHARMACEUTICAL BULLETIN * |
殷缘;张天泰;张大永;: "JAK-3激酶及其抑制剂的研究进展", 药学学报 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115677611A (zh) * | 2021-07-22 | 2023-02-03 | 成都苑东生物制药股份有限公司 | 2H-苯并[b][1,4]恶嗪-3(4H)-酮衍生物 |
Also Published As
Publication number | Publication date |
---|---|
CN112341397B (zh) | 2023-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11337956B2 (en) | IRE-1α inhibitors | |
JP5670359B2 (ja) | Kcnq2/3モジュレータとしての置換されたニコチンアミド | |
US10611770B2 (en) | Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof | |
KR102400920B1 (ko) | 리신 특이적 데메틸라제-1의 억제제 | |
CN113493447A (zh) | Glp-1受体激动剂 | |
RU2617842C2 (ru) | Гетероароматические соединения и их применение в качестве допаминовых D1 лигандов | |
KR20160132470A (ko) | 피페리딘-다이온 유도체 | |
CN104837844B (zh) | 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪 | |
KR101242572B1 (ko) | 5-환 헤테로 아릴로 치환된 프탈라지논 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 약학적 조성물 | |
KR102284205B1 (ko) | 피라졸 유도체 화합물 및 이의 용도 | |
KR20100122512A (ko) | 질소 함유 이환성 복소환 화합물 | |
CN112341397B (zh) | 吡嗪类衍生物或盐、异构体、其制备方法及用途 | |
CN107406425B (zh) | 作为腺苷A2b受体拮抗剂和褪黑激素MT3受体的配体的2-氨基吡啶的衍生物 | |
CN110191879A (zh) | 一种组蛋白甲基转移酶ezh2抑制剂、其制备方法及其医药用途 | |
JP2021525810A (ja) | トリプトファン異化のモジュレーター | |
CA2774008A1 (en) | Toll-like receptor modulators and uses thereof | |
CN112341404B (zh) | 噻唑类衍生物或盐、异构体、其制备方法及用途 | |
NZ579735A (en) | Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor | |
EP3248964B1 (en) | Thiazole modulators of a3 adenosine receptors | |
CN108117551B (zh) | 取代(1H-吡唑[3,4-b]吡啶)脲类化合物及其抗肿瘤用途 | |
CA3090445A1 (en) | Substituted pyrazoles ffa4/gpr120 receptor agonists | |
CN114787145B (zh) | 作为转化生长因子-β受体I/ALK5抑制剂的苯甲酰胺衍生物 | |
CN111187257B (zh) | Ret受体酪氨酸激酶抑制剂 | |
KR20120101068A (ko) | 신규 (헤테로사이클/테트라히드로피리딘)-(피페라지닐)-1-알카논 및 (헤테로사이클/디히드로피롤리딘)-(피페라지닐)-1-알카논유도체, 및 p75 억제제로서의 그의 용도 | |
KR101209702B1 (ko) | 신규 히드록사믹산 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 비정상 세포 성장 질환의 예방 또는 치료용 약학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |